Eli Lilly and Company (NYSE:LLY – Get Free Report) fell 1.2% on Monday . The company traded as low as $1,147.00 and last traded at $1,160.57. 2,818,274 shares traded hands during trading, a decline of 9% from the average session volume of 3,082,697 shares. The stock had previously closed at $1,174.61.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Merida acquisition expands immunology pipeline: Lilly agreed to acquire privately held Merida Biosciences for up to approximately $2.88 billion in cash. Merida’s antibody-engineering platform is designed to remove disease-causing antibodies while preserving normal immune function. Its lead program, MER511, has produced initial Phase 1 data showing reductions in thyroid-stimulating antibodies, potentially supporting treatments for Graves’ disease, thyroid eye disease, food allergies and other autoimmune conditions. Eli Lilly to buy Merida Biosciences in $2.88 billion deal
- Positive Sentiment: Mounjaro receives expanded FDA approval: The FDA approved Mounjaro to reduce cardiovascular risk in high-risk patients with type 2 diabetes, expanding the drug’s addressable market and potentially strengthening Lilly’s diabetes franchise. LLY’s Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
- Positive Sentiment: Encouraging Taltz-Zepbound data: One-year Phase 3b results showed that combining Taltz with Zepbound sustained or improved psoriasis and psoriatic arthritis outcomes, while also improving or maintaining metabolic measures in adults with obesity or overweight. The findings could support broader use of Lilly’s medicines in immunometabolic care. New Phase 3b data on Lilly’s Taltz and Zepbound
- Neutral Sentiment: Deal execution will be key: The Merida transaction diversifies Lilly beyond its blockbuster obesity and diabetes products, but MER511 remains an early-stage asset and the acquisition requires a sizable cash commitment before commercial benefits are established.
- Negative Sentiment: Increasing GLP-1 competition: Investors are monitoring potential threats from Amylyx and Novo Nordisk as rival companies advance competing GLP-1 treatments, including more convenient oral options. Lilly’s dependence on Mounjaro and Zepbound makes sustained market leadership important to its valuation. Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Wall Street Analyst Weigh In
A number of research analysts have commented on LLY shares. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Jefferies Financial Group raised their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. BMO Capital Markets reiterated an “outperform” rating and set a $1,400.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,292.18.
Eli Lilly and Company Price Performance
The firm’s fifty day simple moving average is $1,189.22 and its 200-day simple moving average is $1,065.44. The firm has a market capitalization of $1.09 trillion, a PE ratio of 38.95, a PEG ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.
Insider Activity at Eli Lilly and Company
In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last ninety days. Insiders own 0.14% of the company’s stock.
Institutional Trading of Eli Lilly and Company
A number of hedge funds have recently bought and sold shares of the company. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $30,000. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. raised its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. raised its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Read More
- Five stocks we like better than Eli Lilly and Company
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
